J
10.51
0.03 (0.29%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Jade Biosciences, Inc. | - | - |
AIStockmoo 评分
2.1
| 分析师共识 | 1.0 |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 2.13 |
|
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 0.04% |
| 机构持股比例 | 30.90% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 17.00 (Wedbush, 61.75%) | 购买 |
| 中 | 15.50 (47.48%) | |
| 低 | 14.00 (Guggenheim, 33.21%) | 购买 |
| 平均值 | 15.50 (47.48%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 7.20 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Guggenheim | 16 Jun 2025 | 14.00 (33.21%) | 购买 | 6.99 |
| Wedbush | 15 May 2025 | 17.00 (61.75%) | 购买 | 7.40 |
| 07 May 2025 | 17.00 (61.75%) | 购买 | 9.26 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合